Key result
Patients with type 1 and type 2 diabetes undergoing major surgery had significantly increased odds of having fewer than 15 days at home alive within 30 days postoperatively (adjusted OR 1.42 and 1.13, respectively) compared to non-diabetics.
Why the study?
It was hypothesized that days at home alive up to 30 days after surgery (DAH30) and long-term mortality would be impaired in patients with type 1 or 2 diabetes mellitus undergoing major surgery.
Does diabetes mellitus reduce days at home alive up to 30 days after major non-cardiovascular surgery in adult patients?
Cohort (n=290,306)
Yes
Does diabetes mellitus reduce days at home alive up to 30 days after major non-cardiovascular surgery in adult patients?
Odds Ratio: 1.13 (95% CI 1.09–1.19)
Patients with diabetes undergoing major non-cardiovascular surgery have significantly fewer days at home alive within 30 days and higher 1-year mortality compared to non-diabetics.
May warrant enhanced perioperative risk assessment in diabetes; leaves open whether optimization improves days at home alive.
OBJECTIVE: We hypothesized that days at home alive up to 30 days after surgery (DAH30), a novel patient-centered outcome metric, as well as long-term mortality, would be impaired in patients with type 1 or 2 diabetes mellitus (DM) undergoing major surgery. METHODS: This cohort study investigated patients > 18 years with and without DM presenting for major non-cardiovascular, non-ambulatory surgical procedures at 23 hospitals in Sweden between 2007 and 2014. We identified 290,306 patients. Data were matched with various quality registers. The primary outcome was the composite score, DAH30. The secondary outcome was mortality from 31 to 365 days. Using multivariable logistic regression, significant independent risk factors influencing the primary and secondary outcomes were identified, and their adjusted odds ratios were calculated. RESULTS: Patients with DM type 1 and 2 had significantly lower DAH30 as compared to non-diabetics. Patients with DM were older, had higher co-morbid burden, and needed more emergency surgery. After adjustment for illness severity and age, the odds of having a DAH30 less than 15, indicating death and/or complications, were significantly increased for both type 1 and type 2 diabetes. In the year after surgery, DM patients had a higher mortality as compared to those without diabetes. CONCLUSIONS: The results of this large cohort study are likely broadly generalizable. To optimize patient and societal outcomes, specific perioperative care pathways for patients with diabetes should be evaluated.
No takes yet. Share an insight, caveat, or question.
Habermann et al. (2024) conducted a cohort in Major non-cardiovascular, non-ambulatory surgery (n=290,306). Diabetes mellitus vs. Non-diabetics was evaluated on Days at home alive up to 30 days after surgery (DAH30) < 15 for Type 2 Diabetes (OR 1.13, 95% CI 1.09-1.19). Patients with type 1 and type 2 diabetes undergoing major surgery had significantly increased odds of having fewer than 15 days at home alive within 30 days postoperatively (adjusted OR 1.42 and 1.13, respectively) compared to non-diabetics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: